Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Inclusion Criteria: * Male or female subjects older than the minimum legal adult age (country specific); * Acute symptomatic proximal DVT and/or symptomatic PE confirmed at the site by appropriate diagnostic imaging; * Able to provide written informed consent Exclusion Criteria: * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE; * More than 48 hours pre-treatment with anticoagulant therapy prior to randomization; * Calculated Creatinine clearance (CrCL) \< 30 mL/min; * significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \>\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN; * patients with active cancer for whom long term treatment with (LMW) heparin is anticipated; * active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin or warfarin; * chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs); * treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet therapy; * concurrent treatment with potent P-gp inhibitors; * subjects with any condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study